Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
39 results about "Periostin" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Periostin (POSTN, PN, or osteoblast-specific factor OSF-2) is a protein that in humans is encoded by the POSTN gene. Periostin functions as a ligand for alpha-V/beta-3 and alpha-V/beta-5 integrins to support adhesion and migration of epithelial cells.
Methods and compositions for bone healing by periostin
InactiveUS20110033516A1Shorten healing timePowder deliveryPeptide/protein ingredientsWound healingFracture reduction
The present invention provides methods and compositions for increasing bone production and / or decreasing bone fracture healing time in a subject, by administering an effective amount of periostin and / or active peptides and / or fragments thereof.
Owner:THE MEDICAL UNIV OF SOUTH CAROLINA
Treatment of peritoneal injury using jak inhibitors
The invention provides, in certain embodiments, a method of preventing and / or treating peritoneal injury and / or diminished function by administering an effective amount of one or more inhibitors of JAK. The invention also provides a pharmaceutical composition including a JAK inhibitor for the treatment of peritoneal injury and / or diminished function. In another aspect, the invention provides a method of detecting an indicator of peritoneal injury. The method entails assaying a biological sample for periostin, wherein the presence of periostin at an elevated level indicates the presence and / or degree of peritoneal injury. Also provided, are methods of identifying subject for treatment of peritoneal injury and / or diminished function, methods of determining progression of these conditions, as well as methods of determining subjects' response to treatment.
Owner:LOS ANGELES BIOMEDICAL RES INST AT HARBOR UCLA MEDICAL CENT
Sequences, antibodies, methods and kits for detection and in vitro assay of periostin, in order to provide a diagnosis, follow-up or prognosis of diseases and biological phenomena involving periostin
Detection sequences of periostin having from 6 to 30 amino acids and which include all or part of peptide sequence SEQ ID No. 1, SEQ ID No. 2 or SEQ ID No. 3, or a homologous peptide sequence. Antibodies suitable for specifically recognizing minimally one of these detection sequences, including an anti-periostin antibody, are disclosed. Periostin detection and dosage processes and kits that use these antibodies are also disclosed. A periostin marker for early diagnosis, tracking and prognosis of pathologies that involve periostin, including benign osteolysis such as inflammatory diseases, including osteoarticular diseases, and malignant osteolysis, such as cancers with bone metastases, is provided.
Owner:SYNARC +1
Antibody Against Periostin, and a Pharmaceutical Composition comprising it for Preventing or Treating a Disease in which Periostin is Involved
ActiveUS20090074788A1Improve the quality of lifeVital prognosisNervous disorderDigestive systemDiseaseCell adhesion
The present invention provides an antibody against a periostin isoform having anti-cell adhesive activity, especially an anti-periostin antibody having the ability to neutralize anti-cell adhesive properties, as well as a prophylactic or therapeutic agent for periostin-related diseases comprising the antibody. The present invention also provides methods for detecting and quantifying the periostin isoform in a sample by using the antibody, as well as a method for diagnosing periostin-related diseases comprising measuring the amount of the periostin isoform by the detection or quantification method.
Owner:OSAKA UNIV
Use of periostin as a novel biomarker
InactiveUS20110177613A1Lower Level RequirementsComponent separationIsotope separationNephrosisBiomarker (petroleum)
The invention provides, in certain embodiments, a method of detecting an indicator of renal injury or renal disease. The method entails assaying a urine sample for periostin, wherein the presence of periostin at an elevated level indicates the presence and / or degree of renal injury or renal disease. Also provided, are methods of determining progression of these conditions, as well as methods of determining subjects' response to treatment.
Owner:LOS ANGELES BIOMEDICAL RES INST AT HARBOR UCLA MEDICAL CENT
Humanized anti-Periostin monoclonal antibody as well as preparation method and application of humanized anti-Periostin monoclonal antibody
InactiveCN110551214ASmall toxicityBiologically activeImmunoglobulins against animals/humansAntibody ingredientsComplementarity determining regionHeavy chain
The invention discloses a humanized anti-Periostin monoclonal antibody as well as a preparation method and application of the humanized anti-Periostin monoclonal antibody, and belongs to the technicalfield of medicines. The humanized anti-Periostin monoclonal antibody comprises a light chain complementary determination zone and a heavy chain complementary determination zone, wherein an amino acidsequence of the light chain complementary determination zone is shown in SEQ ID NO.1-3, and an amino acid sequence of the heavy chain complementary determination zone is shown in SEQ ID NO.4-6. The invention also discloses the preparation method and the application of the humanized anti-Periostin monoclonal antibody. Besides the specificity being combined with Periostin proteins and Periostin positive tumor cells, the humanized anti-Periostin monoclonal antibody provided by the invention also has the humanization property and also can reduce toxic side effects of human application.
Owner:杨澜
Biomarkers, uses of biomarkers and a method of identifying biomarkers
InactiveUS20130287801A1Raise the potentialMaximizing numberDepsipeptidesPeptide preparation methodsProphylactic treatmentBiomarker (petroleum)
The invention relates to the use of one or more of protein myoferlin, protein latent-transforming growth factor beta binding protein 2, protein transforming growth factor beta induced protein ig-h3, protein adipocyte enhancer-binding protein 1, protein EMILIN1, protein periostin, protein CD97, protein prolargin, protein Thy-1 membrane glycoprotein, protein growth hormone inducible transmembrane protein, protein biglycan, protein EPCAM and protein EMILIN2 as a biomarker for colorectal carcinoma (CRC) liver metastasis, or a predisposition thereto. The invention also relates to ligands directed to the above-mentioned biomarkers, for use in the therapeutic and / or prophylactic treatment of CRC liver metastasis.
Owner:UNIV LIEGE
Periostin induces proliferation of cardiomyocytes and promotes cardiac regeneration
InactiveUS20100166827A1Slow and reduce and prevent onsetIncreased proliferationBiocidePeptide/protein ingredientsTissue GraftingCardiac muscle
The present invention provides compositions and methods for increasing proliferation, increasing cell cycle activity, and / or proliferation of postmitotic mammalian differentiated cardiomyocytes. The invention can be used to slow, reduce, or prevent the onset of cardiac damage caused by, for example, myocardial ischemia, hypoxia, stroke, or myocardial infarction in vivo. In addition, the methods and compositions of the invention can be used to enhance proliferation of differentiated cardiomyocytes in vitro and / or ex vivo, which can then be used in tissue grafting.
Owner:CHILDRENS MEDICAL CENT CORP
Antibody against periostin, and a pharmaceutical composition comprising it for preventing or treating a disease in which periostin is involved
ActiveUS8017119B2Improve the quality of lifeVital prognosisNervous disorderDigestive systemCell adhesionMedicine
Owner:OSAKA UNIV
Biomarkers for aggressive prostate cancer
ActiveUS20140106369A1Easy to useMicrobiological testing/measurementBiological testingCathepsin LMEMBRANE METALLOENDOPEPTIDASE
The present invention relates to the field of biomarkers and, more specifically, to biomarkers useful in diagnosing aggressive prostate cancer. In specific embodiments, a method for diagnosing aggressive prostate cancer in a patient comprises (a) measuring the levels of one or more biomarkers in a sample collected from the patient; and (b) comparing the levels of the one or more biomarkers with predefined levels of the same biomarkers that correlate to a patient having aggressive prostate cancer and predefined levels of the same biomarkers that correlate to a patient not having aggressive prostate cancer, wherein a correlation to one of the predefined levels provides the diagnosis. In a specific embodiment, the one or more biomarkers may comprise cathepsin-L (CTSL), periostin, microfibrillar-associated protein 4 (MFAP4), collagen XII, neprilysin, clusterin, neutrophil gelatinase associated lipocalin (NGAL), epithelial cell activating molecule (EpCAM), prostate specific antigen (PSA), membrane metallo-endopeptidase (MME) and asporin (ASPN).
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Aptamer for periostin and Anti-cancer composition including same
ActiveUS20150337309A1Inhibits cell adhesionPrevent proliferationOrganic active ingredientsSugar derivativesAptamerDNA Aptamers
This disclosure relates to DNA aptamer specifically binding to periostin, which is cancer-related protein, a composition for inhibiting cancer and / or cancer metastasis and / or a composition for diagnosis of cancer and / or cancer metastasis, comprising the same as an active ingredient, wherein the aptamer has different binding mechanism from the existing antibodies, and thus, may inhibit and diagnose cancer / cancer metastasis more effectively.
Owner:UNIST ULSAN NAT INST OF SCI & TECH
Anti-periostin antibody and pharmaceutical composition for preventing or treating periostin-related disease containing the same
The invention provides an antibody against periostin having an anti-cell adhesion activity, particularly the anti-periostin antibody having an ability to neutralize an anti-cell adhesion action, and a preventive or therapeutic agent for a periostin-related disease using the antibody. It is also intended to provide detection and determination methods for the periostin in a sample using the antibody and a diagnostic method for a periostin-related disease by determining the amount of the periostin by the method.
Owner:OSAKA UNIV
Monoclonal antibody inhibiting tissue organ fibrosis and neovascularization, and preparation method and application thereof
InactiveCN109879963AInhibition formationAvoid causingImmunoglobulins against cytokines/lymphokines/interferonsAntibody ingredientsMicrotubule formationAntibody fragments
The invention provides a monoclonal antibody inhibiting tissue organ fibrosis and neovascularization, and a preparation method and application thereof. The monoclonal antibody is an anti-human periostin monoclonal antibody, and an antibody fragment of the anti-human periostin monoclonal antibody comprises a single-chain variable region fragment, Fab, Fab', F(ab')2 or a nanobody. The anti-human periostin monoclonal antibody can specifically bind to periostin in blood and body fluid of the human body, inhibit periostin from promoting microtubule formation of cells and and have functions of preventing and treating tissue organ fibrosis and neovascularization, and is suitable for preparation of monoclonal antibody drugs for treating tissue organ fibrosis and preparation of drugs for treating tumors.
Owner:HE UNIV
Aptamer for periostin and anti-cancer composition including same
ActiveUS9650638B2Prevent adhesionUsefully usedOrganic active ingredientsSugar derivativesAptamerDNA Aptamers
This disclosure relates to DNA aptamer specifically binding to periostin, which is cancer-related protein, a composition for inhibiting cancer and / or cancer metastasis and / or a composition for diagnosis of cancer and / or cancer metastasis, comprising the same as an active ingredient, wherein the aptamer has different binding mechanism from the existing antibodies, and thus, may inhibit and diagnose cancer / cancer metastasis more effectively.
Owner:UNIST ULSAN NAT INST OF SCI & TECH
Periostin induces proliferation of cardiomyocytes and promotes cardiac regeneration
InactiveUS8936806B2Slow and reduce and prevent onsetIncreased proliferationBiocidePeptide/protein ingredientsRisk strokeCells heart
The present invention provides compositions and methods for increasing proliferation, increasing cell cycle activity, and / or proliferation of postmitotic mammalian differentiated cardiomyocytes. The invention can be used to slow, reduce, or prevent the onset of cardiac damage caused by, for example, myocardial ischemia, hypoxia, stroke, or myocardial infarction in vivo. In addition, the methods and compositions of the invention can be used to enhance proliferation of differentiated cardiomyocytes in vitro and / or ex vivo, which can then be used in tissue grafting.
Owner:CHILDRENS MEDICAL CENT CORP
Treatment of peritoneal injury using JAK inhibitors
Owner:LOS ANGELES BIOMEDICAL RES INST AT HARBOR UCLA MEDICAL CENT
Use of periostin as a novel biomarker
The invention provides, in certain embodiments, a method of detecting an indicator of renal injury or renal disease. The method entails assaying a urine sample for periostin, wherein the presence of periostin at an elevated level indicates the presence and / or degree of renal injury or renal disease. Also provided, are methods of determining progression of these conditions, as well as methods of determining subjects' response to treatment.
Owner:LOS ANGELES BIOMEDICAL RES INST AT HARBOR UCLA MEDICAL CENT
Antibody against periostin, and a pharmaceutical composition comprising it for preventing or treating a disease in which periostin is involved
ActiveUS20120058572A1Improve the quality of lifeVital prognosisAnimal cellsNervous disorderCell adhesionQuantification methods
Owner:OSAKA UNIV
Il-13 antibody and preparation method and use thereof
ActiveUS20190309059A1High affinityInhibition of secretionSerum immunoglobulinsImmunoglobulins against cytokines/lymphokines/interferonsDiseaseBiological activation
The present invention discloses IL-13 antibody, method of its preparation and use thereof. The IL-13 antibody comprises one or more of heavy chain CDR1, heavy chain CDR2 and heavy chain CDR3 of heavy chain variable region of the IL-13 antibody, and / or one or more of light chain CDR1, light chain CDR2, and light chain CDR3 of light chain variable region of the IL-13 antibody. The IL-13 antibody has a high affinity and can significantly inhibit the secretion of thymus activation-regulated chemokine and periostin as well as the expression of vascular cell adhesion molecule-1 induced by IL-13, it can significantly inhibit airway hyperresponsiveness in mice induced by IL-13, and therefore can be used in the preparation of drugs for preventing or treating IL-13 expression or dysfunction related diseases.
Owner:SHANGHAI PHARMAEXPLORER
Tendon repair material, preparation method and application in preparation of tendon repair product
ActiveCN114533959AAvoid the Risk of InflammationAvoid destructionPeptide/protein ingredientsSkeletal disorderAcellular scaffoldAcellular matrix
The invention particularly relates to a tendon repair material, a preparation method and application in preparation of tendon repair products. The existing tendon repair material also has the defects that the induction regeneration effect is insufficient, the mechanical property of the repaired tendon tissue is poor, the ideal release effect is difficult to realize by adding an activity induction factor and the like. Aiming at the problems existing in the prior art, the periostin biologically-crosslinked tendon repair product is provided, periostin is promoted to be crosslinked with an acellular matrix and an acellular scaffold through addition of monoamine oxidase, so that a good slow-release effect is achieved, and after the periostin is implanted into a body, the periostin can be quickly released. The repair material can stimulate the activity of in-vivo amine oxidase, further improves the tendon repair effect, and has good industrialization and treatment prospects.
Owner:山东隽秀生物科技股份有限公司
Cancer remedy containing antibody against peptide encoded by exon-17 of periostin
InactiveCN101888855AImmunoglobulins against growth factorsImmunoglobulins against cell receptors/antigens/surface-determinantsDiseaseCell adhesion
The present invention provides an antibody against a periostin isoform having anti-cell adhesive activity, especially an anti-periostin antibody having the ability to neutralize anti-cell adhesive properties, as well as a prophylactic or therapeutic agent for periostin-related diseases comprising the antibody. The present invention also provides methods for detecting and quantifying the periostin isoform in a sample by using the antibody, as well as a method for diagnosing periostin-related diseases comprising measuring the amount of the periostin isoform by the detection or quantification method.
Owner:OSAKA UNIV
Periostin-induced pancreatic regeneration
A method for regenerating pancreatic tissue using recombinant periostin protein, a nucleic acid encoding said periostin and pharmaceutical compositions comprising said periostin are disclosed. Isolation of a nucleic acid encoding a periostin isoform, panc, is also taught.
Owner:OTTAWA HOSPITAL RES INST
Application of periostin recombinant protein in maintaining the function of tendon stem cells
ActiveCN111826346BEnhanced inhibitory effectPromote aging abilityPeptide/protein ingredientsAntinoxious agentsBiochemistryCellular functions
The invention provides the application of Periostin recombinant protein in maintaining the function of tendon stem cells, including the in vitro culture method of tendon stem cells, which adopts culture medium containing Periostin recombinant protein; the in vitro culture medium of tendon stem cells, wherein the culture medium contains Periostin recombinant protein. The present invention utilizes the Periostin recombinant protein to successfully establish a method for culturing and mass-expanding tendon stem cells in vitro, and can obtain a sufficient number of tendon stem cells. The ability of tendon differentiation makes it possible for tendon stem cells to be used in tendon tissue engineering, repair and regeneration therapy.
Owner:PEKING UNIV SCHOOL OF STOMATOLOGY
Antibodies for treatment and diagnosis
InactiveUS20180193496A1Easy to produceEasy to purifyCompounds screening/testingImmunoglobulins against animals/humansFibronectinPeriostin
The invention relates to the diagnosis and treatment of diseases, including cancer and inflammatory disorders. The invention provides, and involves the use of, antibodies that bind: i) the IIICS isoform of fibronectin, ii) matrix-metalloproteinase 3 (MMP3), iii) periostin, or iv) tenascin-W.
Owner:PHILOGEN SRL LLC
Sequences, antibodies, methods and kits for detection and in vitro assay of periostin, in order to provide a diagnosis, follow-up or prognosis of diseases and biological phenomena involving periostin
InactiveUS9115190B2Immunoglobulins against growth factorsDisease diagnosisPeptide sequenceMalignant osteolysis
Owner:SYNARC +1
IL-13 antibody and preparation method and use thereof
ActiveUS11136387B2High affinityInhibition of secretionSerum immunoglobulinsBiological material analysisDiseaseAntiendomysial antibodies
The present invention discloses IL-13 antibody, method of its preparation and use thereof. The IL-13 antibody comprises one or more of heavy chain CDR1, heavy chain CDR2 and heavy chain CDR3 of heavy chain variable region of the IL-13 antibody, and / or one or more of light chain CDR1, light chain CDR2, and light chain CDR3 of light chain variable region of the IL-13 antibody. The IL-13 antibody has a high affinity and can significantly inhibit the secretion of thymus activation-regulated chemokine and periostin as well as the expression of vascular cell adhesion molecule-1 induced by IL-13, it can significantly inhibit airway hyperresponsiveness in mice induced by IL-13, and therefore can be used in the preparation of drugs for preventing or treating IL-13 expression or dysfunction related diseases.
Owner:SHANGHAI PHARMAEXPLORER
Periostin fragments and use thereof
ActiveUS20180284135A1Immunoglobulins against animals/humansDisease diagnosisDysostosisTherapeutic effect
The present invention relates to biological markers of metabolic bone diseases or disorders such as osteoporosis and related methods using thereof. The invention further relates to the use of those biomarkers and related material and assays in the diagnosis of subjects at risk of developing such disorders or monitoring the effects of a treatment thereof.
Owner:UNIVERSITY OF GENEVA
Periostin-induced pancreatic regeneration
Owner:OTTAWA HOSPITAL RES INST
Compositions and methods for adeno-associated virus mediated gene expression in myofibroblast-like cells
Owner:UNIV OF VIRGINIA ALUMNI PATENTS FOUND
Biomarkers for aggressive prostate cancer
The present invention relates to the field of biomarkers and, more specifically, to biomarkers useful in diagnosing aggressive prostate cancer. In specific embodiments, a method for diagnosing aggressive prostate cancer in a patient comprises (a) measuring the levels of one or more biomarkers in a sample collected from the patient; and (b) comparing the levels of the one or more biomarkers with predefined levels of the same biomarkers that correlate to a patient having aggressive prostate cancer and predefined levels of the same biomarkers that correlate to a patient not having aggressive prostate cancer, wherein a correlation to one of the predefined levels provides the diagnosis. In a specific embodiment, the one or more biomarkers may comprise cathepsin-L (CTSL), periostin, microfibrillar-associated protein 4 (MFAP4), collagen XII, neprilysin, clusterin, neutrophil gelatinase associated lipocalin (NGAL), epithelial cell activating molecule (EpCAM), prostate specific antigen (PSA), membrane metallo-endopeptidase (MME) and asporin (ASPN).
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com